Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF ≥50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Talha, K. M. & Butler, J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin. Cardiol. 45, S31–S39 (2022). A review of the history of classification of heart failure with mildly reduced and preserved ejection fraction and advances in their treatment.
Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021). This paper reports the main findings of the EMPEROR-Preserved clinical trial.
Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020). This paper reports the main findings of the EMPEROR-Reduced clinical trial.
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895–e1032 (2022). A review article that presents the latest comprehensive clinical guidelines on managing heart failure from the major US cardiology associations.
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015). This paper reports the main findings of the EMPA-REG OUTCOME clinical trial.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Anker, S. D. et al. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. Nat. Med. https://doi.org/10.1038/s41591-022-02041-5 (2022).
Rights and permissions
About this article
Cite this article
Empagliflozin benefits in patients with heart failure and preserved ejection fraction. Nat Med 28, 2480–2481 (2022). https://doi.org/10.1038/s41591-022-02050-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02050-4
